Search Results

ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics and biotech company, today announced a collaboration with mProbe, Inc. (“mProbe”), a precision health and medicine company utilizing clinical proteomics in the oncology space, and Dr. Christopher Hartley of Mayo Clinic for the continued development of its BE-Smart Esophageal Pre-Cancer Diagnostic Screening test.

Stella Diagnostics, Inc . (OTC PINK:JMDP) announced today that they have entered into a partnership with mProbe, Inc., a leading biotechnology company based in California.

mProbe Taiwan is a subsidiary biotechnology company of mProbe Inc, committed to promoting human health and wellness by transforming the field of precision health and precision medicine.

ProPhase Labs, Inc. today reported its progress on the commercialization of its breakthrough BE-Smart test for esophageal cancer.

ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today announced important developments in the Company’s efforts to commercialize its novel BE-SMART esophageal cancer diagnostic test.

ProPhase Labs, Inc. announced that its flagship diagnostic test, which is undergoing clinical validation as a laboratory developed test for esophageal cancer screening, was featured in International Journal of Molecular Science, volume 24, no. 4 edition.

ProPhase Labs, Inc., a next generation biotech, genomics, therapeutics and diagnostics company, reported its financial and operational results for the three months ended June 30, 2023.

ProPhase Labs, Inc., a growth oriented and diversified diagnostics, genomics and biotech company, announced that its Board of Directors has authorized a stock repurchase program of up to $6 million in ProPhase Labs’ common stock.

Stella Diagnostics, Inc. announced its STLA101 mass spec proteomic assay was selected as the winner of the “Best Clinical Proteomics Solution of the Year” award for 2021 in the inaugural awards program conducted by BioTech Breakthrough.

The next generation decision-support platform restores an evidence-based approach to molecular diagnostics and oncology